Last updated on November 2019

Dose Optimization Study of Idelalisib in Follicular Lymphoma

Brief description of study

The primary objective of this study is to establish a safe and effective dosing regimen of idelalisib in participants with relapsed or refractory follicular lymphoma (FL) who have no other therapeutic options.

Clinical Study Identifier: NCT02536300

Find a site near you

Start Over